DAWNDay One Biopharmaceuticals, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M

Gross Profit

$26M89.8% margin

Operating Income

-$65M-223.7% margin

Net Income

-$66M-225.0% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

-68.8%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$31M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$583M

Total Liabilities

$80M

Stockholders' Equity

$503M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$0	—
Gross Profit	$26M	-$103,000	+25562.1%
Operating Income	-$65M	-$60M	-9.8%
Net Income	-$66M	-$55M	-20.6%

Revenue Segments

Product

$29M99%

License

$253,0001%

DAWN Q4 2024 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena